Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies
ABSTRACT Objective The use of serotonin 5‐HT1A receptor partial agonists (5‐HT1A‐PAs) as an add‐on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5‐HT1A receptors have been shown to play a role in the pathophysiology of mood disor...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.70023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849683322236567552 |
|---|---|
| author | Risa Yamada Ayumu Wada Andrew Stickley Adrian Newman‐Tancredi Tomiki Sumiyoshi |
| author_facet | Risa Yamada Ayumu Wada Andrew Stickley Adrian Newman‐Tancredi Tomiki Sumiyoshi |
| author_sort | Risa Yamada |
| collection | DOAJ |
| description | ABSTRACT Objective The use of serotonin 5‐HT1A receptor partial agonists (5‐HT1A‐PAs) as an add‐on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5‐HT1A receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5‐HT1A receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5‐HT1A‐PAs to improve cognitive function in patients with depressive symptoms. Methods A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English. Results From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram–tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression. Conclusions Further studies with novel 5‐HT1A receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits. |
| format | Article |
| id | doaj-art-df33e8a231d946fbae17a3a61f73e940 |
| institution | DOAJ |
| issn | 2574-173X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj-art-df33e8a231d946fbae17a3a61f73e9402025-08-20T03:23:56ZengWileyNeuropsychopharmacology Reports2574-173X2025-06-01452n/an/a10.1002/npr2.70023Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled StudiesRisa Yamada0Ayumu Wada1Andrew Stickley2Adrian Newman‐Tancredi3Tomiki Sumiyoshi4Department of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health, National Center of Neurology and Psychiatry Tokyo JapanDepartment of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health, National Center of Neurology and Psychiatry Tokyo JapanDepartment of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health, National Center of Neurology and Psychiatry Tokyo JapanNeurolixis Castres FranceDepartment of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health, National Center of Neurology and Psychiatry Tokyo JapanABSTRACT Objective The use of serotonin 5‐HT1A receptor partial agonists (5‐HT1A‐PAs) as an add‐on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5‐HT1A receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5‐HT1A receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5‐HT1A‐PAs to improve cognitive function in patients with depressive symptoms. Methods A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English. Results From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram–tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression. Conclusions Further studies with novel 5‐HT1A receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits.https://doi.org/10.1002/npr2.700235‐HT1A receptor biased agonists5‐HT1A receptor partial agonistsazapirone derivativecognitive impairmentdepression |
| spellingShingle | Risa Yamada Ayumu Wada Andrew Stickley Adrian Newman‐Tancredi Tomiki Sumiyoshi Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies Neuropsychopharmacology Reports 5‐HT1A receptor biased agonists 5‐HT1A receptor partial agonists azapirone derivative cognitive impairment depression |
| title | Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies |
| title_full | Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies |
| title_fullStr | Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies |
| title_full_unstemmed | Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies |
| title_short | Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies |
| title_sort | augmentation therapy with serotonin 5 ht1a receptor partial agonists on cognitive function in depressive disorders a systematic review of randomized controlled studies |
| topic | 5‐HT1A receptor biased agonists 5‐HT1A receptor partial agonists azapirone derivative cognitive impairment depression |
| url | https://doi.org/10.1002/npr2.70023 |
| work_keys_str_mv | AT risayamada augmentationtherapywithserotonin5ht1areceptorpartialagonistsoncognitivefunctionindepressivedisordersasystematicreviewofrandomizedcontrolledstudies AT ayumuwada augmentationtherapywithserotonin5ht1areceptorpartialagonistsoncognitivefunctionindepressivedisordersasystematicreviewofrandomizedcontrolledstudies AT andrewstickley augmentationtherapywithserotonin5ht1areceptorpartialagonistsoncognitivefunctionindepressivedisordersasystematicreviewofrandomizedcontrolledstudies AT adriannewmantancredi augmentationtherapywithserotonin5ht1areceptorpartialagonistsoncognitivefunctionindepressivedisordersasystematicreviewofrandomizedcontrolledstudies AT tomikisumiyoshi augmentationtherapywithserotonin5ht1areceptorpartialagonistsoncognitivefunctionindepressivedisordersasystematicreviewofrandomizedcontrolledstudies |